Instituut voor Neuropathische Pijn

Many patients suffering from neuropathic pain are currently not optimal treated using the drugs on the market. The total value of the neuropathic pain market is supposed to double from 2006 to reach over$7 billion by 2016. There is a lot of space in the marketplace for improved pain management.

In our institute we are specialized inthe treatment of neuropathic pain and adbvising R&D processesrelated to the identification of new potential painkillers forneuropathic pain. A short explanation of the experience we have inhelping pharmaceutical companies developing new drugs, by professor JanM. Keppel Hesselink, MD, PhD, consultant.

R&D for new drugs in neuropathic pain, role of the consulting pain specialist Jan M. Keppel Hesselink, MD, PhD, professor in pharmacology and past VP R&D CNS for Bayer AG. Jan Keppel Hesselink works as a consultant to the pharmaceutical industry at the institute for the treatment of neuropathic pain in the Netherlands, www.neuropathie.nu. The institute developed the biggest website on neuropathic pain, containing 500 articles and more than 1000 pages on topics related to science and treatment of neuropathic pain.

Dr Keppel Hesselink runs a regular Pain Medicine clinical practice, which treats patients suffering from various conditions associated with neuropathic pain, with a particular focus on peripheral polyneuropathy, CIAP, diabetic neuropathy and chemotherapy induced neuropathy.